Articles by Patrick Clinton - Pharmaceutical Executive

ADVERTISEMENT

Articles by Patrick Clinton

Being Bob: Q&A with Robert Essner

Jun 1, 2008

An industry legend weighs in on leadership, research, and sales models. Q&A with outgoing Wyeth Chairman Bob Essner

Everybody's Right

Jun 1, 2008

The great debate on DTC advertising is heating up again. We're going to be hearing a lot about fair balance and risk communication and costs. But what about the patients?

Chantix Under Fire

May 28, 2008

A new study ranks Pfizer's anti-smoking drug as number one in generating adverse event reports. That's bad news for Pfizer—but in the long run, what does it really mean?

Molecular Fraud

Apr 1, 2008

The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos

Molecular Fraud

Apr 1, 2008

The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos

Come in Out of the Rain

Mar 1, 2008

For pharma to function, it needs a whole network that commands trust. The only alternative is the sort of regulation by mass tort that we've been sliding into in recent years

Calling All Leaders

New from Pharm Exec: an awards program for young pharma leaders, a redesigned Web site, a blog, and expanded coverage
Feb 1, 2008

New from Pharm Exec: a blog, expanded tech and deals coverage, and a new awards program for emerging pharma leaders

Not Enough Science

Jan 1, 2008

A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?

After the Crash

Dec 1, 2007

For several decades, pharma got the message that promotion could make consumers want to use new drugs. The system didn't work with Pfizer's Exubera. That's surprising news, but is it bad news?

ADVERTISEMENT

Click here